Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI versus usual maintenance therapy in COPD over 12 months
2011-002452-13Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluticasone, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Nov 2011; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-002452-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002452-13.